844-4CHILDRENS
844-4CHILDRENS
All Results
Doctors
Locations
Conditions & Treatments
Departments & Programs
Articles & Media
Clinical Trials
Search for actively enrolling clinical trials
Clinical Trials
Clinical trials are patient studies that test new treatments and therapies. The main purpose of clinical trials is to find a better way to prevent, diagnose or treat a disease. Everyone who participates in clinical trials is a volunteer.
At Children’s Health℠, research is a way of life and a way forward to better care. Our physicians and scientists actively engage in research and innovation, every day. Current research – in conjunction with UT Southwestern – focuses on a number of critical areas in pediatric health, expanding treatment options and redefining what is possible in pediatric medicine.
Featured Clinical Trials
-
Study of Efficacy and Safety of CTL019 in Pediatric All Patients
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of an experimental therapy called CTL019 T-cells in pediatric patients with B-cell acute lymphoblastic leukemia, who are refractory to standard chemotherapy regimen or relapsed after allogeneic stem cell transplant.
-
Oral TRK Inhibitor LOXO-101 (Larotrectinib) for Treatment of Advanced Pediatric Solid or Primary Central Nervous System Tumors (SCOUT)
This is a multicenter, open label, Phase 1/2 study in pediatric patients with advanced solid or primary CNS tumors. LOXO‑101 (larotrectinib) will be administered orally (PO) twice daily (BID), with the dose adjusted by body surface area (BSA).
-
HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors
The purpose of this study is to determine whether Doxil (liposomal doxorubicin) given prior to MR-HIFU Hyperthermia is safe for the treatment of pediatric and young adult patients with recurrent and refractory solid tumors.
-
CRAD001CUS224T, Phase II Study of Everolimus (RAD001, AFINITOR®) for Children with Recurrent or Progressive Ependymoma
This study is a Phase ii Study of everolimus (RaD001, afinitor[RegisteredTM]) for Children with Recurrent or Progressive ependymoma. The Primary aim of the study is to determine if everolimus has anti-tumor activity against pediatric ependymoma.
-
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
The purpose of this study is to find out if the combination of an mTOR inhibitor (sirolimus) with an EGFR inhibitor (erlotinib) is effective at treating relapsed or refractory germ cell tumors, and to find out what the side-effects of this regimen are.
-
Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
The purpose of this research study is to make 131I-MIBG therapy available to patients with advanced neuroblastoma, pheochromocytoma, or paraganglioma and further assess the side effects of 131I-MIBG therapy.